BMS tests Icahn with $4.5 billion ImClone offer
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibbhas made a $4.5 billion cash offer to acquire ImClone Systems- a move which would consolidate the firms' six year relationship. The $60 per share offer represents a 30% premium over ImClone's closing price on July 30th and values the company at $5.2 billion.